EP3768387A4 - IMMUNOSUPPRESSIVE MATERIALS AND RELATED PROCEDURES - Google Patents

IMMUNOSUPPRESSIVE MATERIALS AND RELATED PROCEDURES Download PDF

Info

Publication number
EP3768387A4
EP3768387A4 EP19772204.4A EP19772204A EP3768387A4 EP 3768387 A4 EP3768387 A4 EP 3768387A4 EP 19772204 A EP19772204 A EP 19772204A EP 3768387 A4 EP3768387 A4 EP 3768387A4
Authority
EP
European Patent Office
Prior art keywords
immunosuppressive
materials
related procedures
procedures
immunosuppressive materials
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19772204.4A
Other languages
German (de)
French (fr)
Other versions
EP3768387A1 (en
Inventor
Shaoyi Jiang
Bowen Li
Priyesh Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of EP3768387A1 publication Critical patent/EP3768387A1/en
Publication of EP3768387A4 publication Critical patent/EP3768387A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909—Micelles formed by phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F299/00—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
EP19772204.4A 2018-03-23 2019-03-25 IMMUNOSUPPRESSIVE MATERIALS AND RELATED PROCEDURES Pending EP3768387A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647534P 2018-03-23 2018-03-23
PCT/US2019/023921 WO2019183637A1 (en) 2018-03-23 2019-03-25 Immunosuppressive materials and related methods

Publications (2)

Publication Number Publication Date
EP3768387A1 EP3768387A1 (en) 2021-01-27
EP3768387A4 true EP3768387A4 (en) 2022-01-05

Family

ID=67988003

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19772204.4A Pending EP3768387A4 (en) 2018-03-23 2019-03-25 IMMUNOSUPPRESSIVE MATERIALS AND RELATED PROCEDURES

Country Status (5)

Country Link
US (2) US12194103B2 (en)
EP (1) EP3768387A4 (en)
JP (2) JP7534782B2 (en)
CN (2) CN112384284B (en)
WO (1) WO2019183637A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183637A1 (en) * 2018-03-23 2019-09-26 University Of Washington Immunosuppressive materials and related methods
US20250268833A1 (en) * 2020-08-28 2025-08-28 Board Of Regents For The Oklahoma Agricultural And Mechanical Colleges Zwitterionic Hydrogels and Methods of Making and Using Same for Protein Therapy
JP2024518727A (en) * 2021-04-22 2024-05-02 トラスティーズ オブ タフツ カレッジ Crosslinked zwitterionic polymer networks and their use in membrane filters
CN113336795A (en) * 2021-06-02 2021-09-03 中国科学院长春应用化学研究所 Choline phosphoric acid monomer and polymer and application thereof
EP4452351A4 (en) * 2021-12-20 2026-03-18 Univ Florida MICROGELS, METHOD FOR THE PREPARATION OF MICROGELS AND METHOD FOR THE USE OF MICROGELS
US20250064741A1 (en) * 2021-12-21 2025-02-27 Cornell University Methods for enhanced nucleic acid delivery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004097A1 (en) * 1997-12-31 2003-01-02 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
WO2011057224A2 (en) * 2009-11-06 2011-05-12 University Of Washington Through Its Center For Commercialization Zwitterionic polymer bioconjugates and related methods
WO2017003639A2 (en) * 2015-06-02 2017-01-05 University Of Washington Free-standing non-fouling polymers, their compositions, and related monomers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716597A (en) 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
US6583251B1 (en) 1997-09-08 2003-06-24 Emory University Modular cytomimetic biomaterials, transport studies, preparation and utilization thereof
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
WO2005087221A1 (en) 2004-03-15 2005-09-22 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
CA2526541C (en) 2004-12-01 2013-09-03 Tyco Healthcare Group Lp Novel biomaterial drug delivery and surface modification compositions
WO2007002886A2 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes
US20100324124A1 (en) 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Compositions and methods relating to DNA-based particles
EP2451485B1 (en) 2009-07-07 2016-03-02 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance
US8778379B2 (en) 2010-01-22 2014-07-15 Concept Medical Research Private Ltd Insertable medical devices with a porous bed for delivering nano-carriers to a target site and methods of preparing the same
WO2012024233A2 (en) * 2010-08-14 2012-02-23 The Regents Of The University Of California Zwitterionic lipids
DK2471827T3 (en) 2010-12-30 2013-11-11 Universitaetsklinikum Freiburg Covalently bonded antimicrobial polymers
US9567357B2 (en) * 2011-06-24 2017-02-14 Biointeractions Ltd. Biocompatible, biomimetic ampholyte materials
EP2763659B1 (en) 2011-10-06 2017-07-19 The Research Foundation Of State University Of New York Compositions and methods for immune tolerance induction
SG11201403406PA (en) 2011-12-19 2014-12-30 Stephen Micheal Henry Biocompatible method of functionalising substrates with inert surfaces
WO2013155487A1 (en) 2012-04-12 2013-10-17 Yale University Vehicles for controlled delivery of different pharmaceutical agents
JP6206916B2 (en) 2013-11-15 2017-10-04 国立研究開発法人物質・材料研究機構 Intercellular signal transduction molecule production signal-inducing functional polymer and synthesis method thereof
US20170348415A1 (en) * 2014-09-03 2017-12-07 Moderna Therapeutics, Inc. Tolerogenic compositions and methods
WO2019183637A1 (en) * 2018-03-23 2019-09-26 University Of Washington Immunosuppressive materials and related methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004097A1 (en) * 1997-12-31 2003-01-02 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
WO2011057224A2 (en) * 2009-11-06 2011-05-12 University Of Washington Through Its Center For Commercialization Zwitterionic polymer bioconjugates and related methods
WO2017003639A2 (en) * 2015-06-02 2017-01-05 University Of Washington Free-standing non-fouling polymers, their compositions, and related monomers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM HEEJIN ET AL: "Synthesis of biomembrane-mimic polymers with various phospholipid head groups", POLYMER, ELSEVIER, AMSTERDAM, NL, vol. 55, no. 2, 17 December 2013 (2013-12-17), pages 517 - 524, XP028817699, ISSN: 0032-3861, DOI: 10.1016/J.POLYMER.2013.12.020 *
LAMPKINS ANDREW J. ET AL: "Bio-orthogonal Phosphatidylserine Conjugates for Delivery and Imaging Applications", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 73, no. 16, 1 August 2008 (2008-08-01), pages 6053 - 6058, XP055866608, ISSN: 0022-3263, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/jo8011336> DOI: 10.1021/jo8011336 *
See also references of WO2019183637A1 *

Also Published As

Publication number Publication date
EP3768387A1 (en) 2021-01-27
CN112384284B (en) 2024-08-27
WO2019183637A1 (en) 2019-09-26
JP2024167192A (en) 2024-12-03
JP2021519275A (en) 2021-08-10
US20210023228A1 (en) 2021-01-28
US20250375527A1 (en) 2025-12-11
CN112384284A (en) 2021-02-19
US12194103B2 (en) 2025-01-14
JP7534782B2 (en) 2024-08-15
CN119158032A (en) 2024-12-20

Similar Documents

Publication Publication Date Title
EP3737229C0 (en) SYSTEM AND PROCEDURE
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND USES THEREOF
EP3793214C0 (en) BONE-CONDUCTING LOUDSPEAKER AND TEST METHODS THEREFOR
EP3217046C0 (en) ORDER AND RELATED PROCEDURES
EP3551970A4 (en) GAS METERS AND RELATED PROCEDURES
EP3638157A4 (en) EXPANDABLE INTER SPERAL IMPLANT AND RELATED PROCEDURE
EP3531835C0 (en) MATERIALS AND METHODS FOR COMBATTING NEMATODS
EP3555422A4 (en) METHODS AND DEVICES FOR EVALUATING THE CONTENTS OF MATERIALS
EP3580013A4 (en) ENERGY-PROCESSED POLYCRYSTALLINE DIAMOND COMPACT AND ASSOCIATED PROCESSES
EP3532100A4 (en) ANTI-PD-L1 ANTIBODIES AND VARIANTS
EP3325513B1 (en) Anti-PD-L1 antibodies and their uses
EP3464349A4 (en) COMPOSITIONS AND PROCEDURES FOR STAPHYLOCOCCLE LEUKOTOXIN ANTIBODIES
EP3601993A4 (en) UNDERWATER SAMPLING DEVICES AND METHODS FOR THEREFORE
EP3544535A4 (en) TUMORABLATION DEVICES AND RELATED METHODS
EP3904382A4 (en) ANTI-IL-23P19 ANTIBODIES AND USES THEREOF
EP3566003A4 (en) MULTIPLE STATIC VIEW AND PROCEDURE
EP3574245A4 (en) EXHAUST CLAMP AND PROCEDURE
EP4071172A4 (en) ANTI-LILRB1 ANTIBODIES AND USES THEREOF
EP3732203A4 (en) ANTIBODIES AND VARIANTS THEREOF AGAINST PD-L1
EP3534910A4 (en) THERAPEUTICS AND PROCEDURES
CR20180296A (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
EP4025609A4 (en) ANTI-STEAP1 ANTIBODIES AND USES THEREOF
EP3868408A4 (en) ANTISYCHOTIC AND ITS USE
EP3426262C0 (en) CROSSLINKING AGENTS AND ASSOCIATED METHODS
EP3525835A4 (en) SHUNT RINSER AND RELATED PROCEDURES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20211207

RIC1 Information provided on ipc code assigned before grant

Ipc: C08F 293/00 20060101ALI20211201BHEP

Ipc: A61K 38/44 20060101ALI20211201BHEP

Ipc: A61P 37/08 20060101ALI20211201BHEP

Ipc: A61P 37/06 20060101ALI20211201BHEP

Ipc: A61P 37/02 20060101ALI20211201BHEP

Ipc: A61K 47/58 20170101AFI20211201BHEP